Hoth Therapeutics Inc (HOTH) - Total Assets
Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) holds total assets worth $9.24 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hoth Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
Hoth Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Hoth Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Hoth Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Hoth Therapeutics Inc's total assets of $9.24 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.3% |
| Accounts Receivable | $46.77K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Hoth Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Hoth Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hoth Therapeutics Inc's current assets represent 99.1% of total assets in 2024, a decrease from 99.7% in 2017.
- Cash Position: Cash and equivalents constituted 91.3% of total assets in 2024, down from 99.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Hoth Therapeutics Inc Competitors by Total Assets
Key competitors of Hoth Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hoth Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.81 | 10.16 | 15.32 |
| Quick Ratio | 8.81 | 10.16 | 15.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.91 Million | $7.43 Million | $4.47 Million |
Hoth Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Hoth Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 1.47 |
| Asset Growth Rate (YoY) | -24.7% |
| Total Assets | $7.71 Million |
| Market Capitalization | $11.34 Million USD |
Valuation Analysis
Above Book Valuation: The market values Hoth Therapeutics Inc's assets above their book value (1.47x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Hoth Therapeutics Inc's assets decreased by 24.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hoth Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Hoth Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.71 Million | -24.70% |
| 2023-12-31 | $10.24 Million | +51.54% |
| 2022-12-31 | $6.76 Million | -38.47% |
| 2021-12-31 | $10.99 Million | +109.53% |
| 2020-12-31 | $5.24 Million | +84.86% |
| 2019-12-31 | $2.84 Million | +462.82% |
| 2018-12-31 | $503.92K | -59.16% |
| 2017-12-31 | $1.23 Million | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell deriv… Read more